Sponsored by:

Molecular Imaging: Page 287

Navidea launches phase II trial
By AuntMinnie.com staff writers
Radiopharmaceutical developer Navidea Biopharmaceutical has enrolled the first patient in a phase II trial of its fluorine-18 NAV4694 radiopharmaceutical candidate, which is designed as an aid in detecting cerebral beta-amyloid plaque in subjects diagnosed with probable Alzheimer's disease.
September 17, 2012
NOPR asks CMS to ease coverage rules for PET
By AuntMinnie.com staff writers
The National Oncologic PET Registry (NOPR) is asking the U.S. Centers for Medicare and Medicaid Services (CMS) to make reimbursement for oncology PET studies easier by ending its requirement that payments be made under its coverage with evidence development (CED) statute.
September 16, 2012
GE contributes $33M to R&D center in Wis.
By AuntMinnie.com staff writers
GE Healthcare has committed an investment of $32.9 million to build a state-of-the-art research facility in Wisconsin.
September 13, 2012
Piramal moves ahead with florbetaben PET for Alzheimer's
By Wayne Forrest
Since its acquisition of Bayer Pharma's molecular imaging agent portfolio five months ago, Piramal Imaging has been making steady progress in advancing its PET tracer designed to detect beta-amyloid deposits in the brain, which have been linked to early signs of Alzheimer's disease.
September 13, 2012
2012 09 10 09 25 16 46 Mol Insider Piramal Florbetaben Pet Images Thumb
Nordion realigns into 2 business units
By AuntMinnie.com staff writers
Nordion is realigning to create two business units: Targeted Therapies and Specialty Isotopes. The Specialty Isotopes segment will include Sterilization Technologies and Medical Isotopes.
September 12, 2012
ASNC: U.S. cardiologists using less imaging
By AuntMinnie.com staff writers
U.S. cardiologists are seeing more patients than ever before, yet on average they are performing fewer advanced nuclear imaging tests on those patients, according to a new report from the American Society of Nuclear Cardiology (ASNC).
September 12, 2012
FDA clears C-11 choline PET for prostate cancer
By AuntMinnie.com staff writers
The U.S. Food and Drug Administration (FDA) has approved the production and use of PET radiopharmaceutical carbon-11 (C-11) choline injection to detect recurrent prostate cancer, the agency announced.
September 11, 2012
Navidea fails to get clearance for Lymphoseek
By AuntMinnie.com staff writers
The U.S. Food and Drug Administration has elected not to approve radiopharmaceutical developer Navidea Biopharmaceuticals' new drug application for its Lymphoseek radiopharmaceutical.
September 10, 2012
GE promotes phase III flutemetamol results
By AuntMinnie.com staff writers
GE Healthcare said pooled results from phase III brain autopsy and biopsy studies using its F-18 flutemetamol PET imaging agent demonstrated a strong concordance between the flutemetamol images and beta amyloid brain pathology associated with Alzheimer's disease.
September 10, 2012
Digirad taps new CFO
By AuntMinnie.com staff writers
Nuclear medicine firm Digirad has appointed Jeffry Keyes as CFO, effective immediately.
September 10, 2012
JAMA: SPECT/CT works well to guide node excision
By Wayne Forrest
Using SPECT/CT scans to guide the excision of sentinel lymph nodes in melanoma patients produced both a greater rate of metastasis detection and higher disease-free survival rates, according to a study in the September 12 issue of the Journal of the American Medical Association.
September 10, 2012
Nordion loses case against AECL
By AuntMinnie.com staff writers
Nordion has lost its arbitration case against Atomic Energy of Canada (AECL) seeking damages from AECL's canceled construction of the MAPLE nuclear reactor facilities.
September 9, 2012
Previous Page
Page 287 of 611
Next Page